100 related articles for article (PubMed ID: 6453169)
21. Effect of subinhibitory doses of clindamycin on the virulence of Bacteroides fragilis: role of lipopolysaccharide.
Zaleznik DF; Zhang ZL; Onderdonk AB; Kasper DL
J Infect Dis; 1986 Jul; 154(1):40-6. PubMed ID: 3711690
[TBL] [Abstract][Full Text] [Related]
22. Comparative in-vitro activity of cefamandole, cefoxitin, cefuroxime and cephalothin.
Brorson JE; Norrby R
Scand J Infect Dis Suppl; 1978; (13):88-93. PubMed ID: 278150
[No Abstract] [Full Text] [Related]
23. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
24. beta-Lactamase activity in human pus.
Bryant RE; Rashad AL; Mazza JA; Hammond D
J Infect Dis; 1980 Oct; 142(4):594-601. PubMed ID: 6969281
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea.
Lee K; Shin HB; Chong Y
Yonsei Med J; 1998 Dec; 39(6):578-86. PubMed ID: 10097686
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
27. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Wells CL; Arland LA; Simmons RL; Rotstein OD
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
[TBL] [Abstract][Full Text] [Related]
28. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
[TBL] [Abstract][Full Text] [Related]
29. The activity of cephalosporins on beta-lactamase-producing Neisseria gonorrhoeae.
Phillips I; Shannon K
Scand J Infect Dis Suppl; 1978; (13):23-6. PubMed ID: 98833
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the in-vivo efficacy of Sch 34343.
Loebenberg D; Moss EL; Rudeen J; Menzel F; Hare RS; Oden EM; Lin CC; Miller GH
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():207-18. PubMed ID: 3897173
[TBL] [Abstract][Full Text] [Related]
31. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
32. Bacteroides fragilis resistant to metronidazole, clindamycin and cefoxitin.
Brogan O; Garnett PA; Brown R
J Antimicrob Chemother; 1989 Apr; 23(4):660-2. PubMed ID: 2745269
[No Abstract] [Full Text] [Related]
33. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of antimicrobial resistance and resistance transfer in anaerobic bacteria.
Tally FP; Malamy MH
Scand J Infect Dis Suppl; 1982; 35():37-44. PubMed ID: 6300995
[TBL] [Abstract][Full Text] [Related]
35. [Cefoxitin, a new beta-lactamase stable antibiotic].
Simon C; Meyer E; Malerczyk
Arzneimittelforschung; 1978; 28(9):1541-5. PubMed ID: 314296
[No Abstract] [Full Text] [Related]
36. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
Nord CE; Olsson-Liljequist B
Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
[TBL] [Abstract][Full Text] [Related]
37. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
Jones RN; Barry AL; Packer RR
Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
[TBL] [Abstract][Full Text] [Related]
38. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
39. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
Watt B; Naden MG
Chemioterapia; 1988 Aug; 7(4):264-6. PubMed ID: 2902937
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
